 |
Lupus Erythematosus, Systemic - Immunology
Research News and Information
Definition of 'Lupus Erythematosus, Systemic'A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. |
Saturday, November 21, 2009
Novel evidence-based systemic lupus erythematosus responder index.
13 Sep 2009 
OBJECTIVE: To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. METHODS: Data from a randomized, double-blind, ... Read more...
13 Sep 2009 OBJECTIVE: To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS: Patients with a Safety of Estrogens ... Read more...
CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
2 Sep 2009 Infiltration of T cells into the kidney is a typical feature of human and experimental lupus nephritis that contributes to renal tissue injury. The chemokine receptor CXCR3 is highly expressed on Th1 cells and is supposed to be crucial for their ... Read more...
Latest indexed articles for 'Lupus Erythematosus, Systemic - Immunology'
These are the very latest articles for this heading:
- Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus.
30 Oct 2009 - Novel evidence-based systemic lupus erythematosus responder index. 13 Sep 2009
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. 13 Sep 2009
- CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. 2 Sep 2009
- Unraveling the etiology of systemic autoimmune diseases: peering into the preclinical phase of disease. 30 Aug 2009
- B cell depletion in lupus and Sjögren's syndrome: an update. 30 Aug 2009
- Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? 30 Aug 2009
- Drug-induced autoimmunity. 30 Aug 2009
- Pathogenesis of kidney disease in systemic lupus erythematosus. 30 Aug 2009
- Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. 30 Aug 2009
- T-cell and B-cell signaling biomarkers and treatment targets in lupus. 30 Aug 2009
- Type I interferon and lupus. 30 Aug 2009
- Predictors of damage progression in Portuguese patients with systemic lupus erythematosus. 30 Aug 2009
- Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. 30 Aug 2009
- Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome. 30 Aug 2009
- The role of iNKT cells in the immunopathology of systemic lupus erythematosus. 30 Aug 2009
- Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways. 30 Aug 2009
- Defensins in systemic lupus erythematosus. 30 Aug 2009
- Natural antibodies against phosphorylcholine in cardiovascular disease. 30 Aug 2009
- Regulatory B cells in autoimmune diseases: how do they work? 30 Aug 2009
See a longer list of these articles.
Technical information about 'Lupus Erythematosus, Systemic'
Definition: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Descriptor UI: D008180
Alternative terms: Lupus Erythematosus, Systemic; Systemic Lupus Erythematosus; Lupus Erythematosus Disseminatus; Libman-Sacks Disease; Disease, Libman-Sacks; Libman Sacks Disease;
Related Mesh Headings: Lupus Coagulation Inhibitor; Antiphospholipid Syndrome; Vasculitis, Central Nervous System;
Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;
Tree Number: C17.300.480; C20.111.590;
Technical Notes: if not specified as "systemic" it is still probably correct to index here, not also discoid; LUPUS NEPHRITIS is also available; LE CELLS see NEUTROPHILS is also available: use LUPUS ERYTHEMATOSUS, SYSTEMIC /blood or /pathol + NEUTROPHILS for discussion of the LE cells as cells; DF: SLE